OSIRIS project cooperation with General University Hospital in Prague

Subject: Letter of Intent for a Grant Application within the ERA4Health call EffecTrial 2025: **"FOSTERING PRAGMATIC COMPARATIVE-EFFECTIVENESS TRIALS IN NON-COMMUNICABLE DISEASES"**

Dear Members of the Grant Review Committee,

we are providing this letter to express our enthusiastic support for the grant application entitled: **Out-of-hospital refractory cardiac arrest treated with extracorporeal cardiopulmonary resuscitation: "The OSIRIS ECPR trial".**

As the responsible investigators within our center, we have closely followed the work of the research team led by Professor Jan Bělohlávek, MD., PhD in the field of resuscitation and Extracorporeal Cardiopulmonary Resuscitation (ECPR).

Refractory cardiac arrest is a severe medical condition with high mortality rates and the utilization of ECPR has emerged as a promising intervention to improve outcomes in these patients. However, current level of evidence is still not complete to consider this intervention to become a state of the art.

Therefore, the proposed multicenter randomized controlled trial fulfils the urgent need to provide high quality data to solve this critical gap in current resuscitation medicine. Sudden cardiac arrest has been acknowledged as a high priority topic by major European societies (European Society of Cardiology, European Resuscitation Council, and EuroELSO). The project directly addresses the key goals of the EU Cardiovascular Health Plan to significantly lower deaths from CVD diseases, ensure equitable access to care, and improve health and quality of life for individuals affected by CVD.

The potential impact of this project is enormous, not just by means of generating scientific evidence, but also potentially safe many lives within the EU in the future, if the intervention proves to be beneficial. ECPR has the potential not only to save lives and improve medical outcomes, but also improve recovery and return to normal and productive life.

The requested grant funding will provide crucial support for essential research crosscutting activities like overall study management, data acquisition, analysis, cleaning and verification. The rest of the resources, kindly provided by the institutional support from GUH, will support our local activities in study management and execution. We acknowledge and appreciate GUH´s willingness to provide this unrestricted help and accept it thankfully.

As we consider this trial scientifically highly relevant and contributory with potentially high impact on future resuscitation medicine, we pledge our active commitment to OSIRIS trial even with a limited funding as described above. The potential impact on patient care and the advancement of knowledge in the field of resuscitation science make our participation highly deserving.

On behalf of the research team in Bern, Switzerland



15.Jan.2026 Prof. Dr. med. Wolf Hautz, MME